Your Messages Inbox
Your Article Summary
See Latest ArticlesGlaxoSmithKline and XenoPort announce extension of GSK1838262 FDA review date to 2010
GlaxoSmithKline, 11/10/09
GlaxoSmithKline and XenoPort, Inc. announced that the U.S. Food and Drug Administration has extended the original Prescription Drug User Fee Act goal date for its review of the New Drug Application for GSK1838262/XP13512 to 2010. The original PDUFA date for this NDA review was November 2009.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09
Article Search
Sponsor